Why the study?
Genetic contributions to early-onset HF are incompletely understood, and data on genetic testing in advanced HF patients undergoing heart transplantation are limited.
Does whole genome sequencing identify a high prevalence of pathogenic variants in patients with early-onset advanced heart failure undergoing heart transplantation?
Does whole genome sequencing identify a high prevalence of pathogenic variants in patients with early-onset advanced heart failure undergoing heart transplantation?
Answers are grounded in this paper and cite their sources.
Whole genome sequencing reveals a high prevalence (34%) of pathogenic variants in early-onset advanced heart failure patients, which cannot be reliably ruled out by the absence of family history.
The genetic contributions to early onset heart failure (HF) are incompletely understood. Genetic testing in advanced HF patients undergoing heart transplantation (HTx) may yield clinical benefits, but data is limited. We performed deep-coverage whole genome sequencing (WGS) in 102 Swedish HTx recipients. Gene lists were compiled through a systematic literature review. Variants were prioritized for pathogenicity and classified manually. We also compared polygenic HF risk scores to a population-based cohort. We found a pathogenic (LP/P) variant in 34 individuals (34%). Testing yield was highest in hypertrophic (63% LP/P carriers), dilated (40%) and arrhythmogenic right ventricular (33%) cardiomyopathy and lower in ischemic cardiomyopathy (10%). A family history was more common in LP/P variant carriers than in non-carriers but was present in less than half of carriers (44% vs 13%, P < 0.001), whereas age was similar. Polygenic risk scores were similar in HTx recipients and the population cohort. In conclusion, we observed a high prevalence of pathogenic cardiomyopathy gene variants in individuals with early-onset advanced HF, which could not accurately be ruled out by family history and age. In contrast, we did not observe higher polygenic risk scores in early onset advanced HF cases than in the general population.
No takes yet. Share an insight, caveat, or question.
Linnér et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: